Disease · MONDO_0020511
precursor B-cell acute lymphoblastic leukemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. precursor B-cell acute lymphoblastic leukemia. Diseases, record MONDO_0020511. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020511
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
B cell precursor type acute leukaemia, B cell precursor type acute leukemia, B-precursor ALL, precursor B-cell acute lymphoblastic leukemia/lymphoma, precursor B-cell acute lymphocytic leukaemia, precursor B-cell acute lymphocytic leukemia, precursor B-cell acute lymphocytic leukemia/lymphoma, precursor B-lymphoblastic leukaemia, precursor B-lymphoblastic leukaemia (B-precursor ALL), precursor B-lymphoblastic leukemia, precursor B-lymphoblastic leukemia (B-precursor ALL)
- Open Targets
Drugs53
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BLINATUMOMAB | CHEMBL1742992 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CYTARABINE | CHEMBL803 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 5 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| MERCAPTOPURINE | CHEMBL1200751 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 3 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 53
See all 53 drugsTargets113
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | 9 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 4 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 3 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 4 | Bcr/Abl fusion protein inhibitor | Phase 3 | https://conductscience.org/library/genes/613 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| TUBA1A | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
1 to 10 of 113
See all 113 targetsTrials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | Phase 3 | 111 | 2020-07-13 | Leukemia, Acute Lymphoblastic | BLINATUMOMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01700946 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | Phase 2 | 80 | 2022-09-28 | Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma | ALDESLEUKIN, CLOFARABINE, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, MITOXANTRONE HYDROCHLORIDE, PEGASPARGASE, RITUXIMAB, VINBLASTINE, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02879695 | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | Phase 1 | 28 | 2024-10-16 | Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia | BLINATUMOMAB, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | Phase 3 | 5,000 | Acute Lymphoblastic Leukemia, Pediatric | BLINATUMOMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, CYTARABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06860269 | A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia | Phase 2/3 | 1,200 | Acute Lymphoblastic Leukemia | BLINATUMOMAB, ISATUXIMAB, PONATINIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00327678 | Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults | Phase 3 | 1,080 | Leukemia, Lymphocytic | IMATINIB MESYLATE, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03117751 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Phase 2/3 | 790 | Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma | BLINATUMOMAB, BORTEZOMIB, CALASPARGASE PEGOL, CLOFARABINE, CRISANTASPASE, CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, IDARUBICIN, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PEGASPARGASE, PREDNISONE, RUXOLITINIB, VINCRISTINE, VORINOSTAT | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | Phase 3 | 750 | B-Cell Acute Lymphoblastic Leukaemia | BLINATUMOMAB, INOTUZUMAB OZOGAMICIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01228331 | Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL | Phase 2/3 | 745 | Leukemia | AMSACRINE, CLOFARABINE, CYCLOPHOSPHAMIDE, DAUNORUBICIN HYDROCHLORIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE PHOSPHATE, MERCAPTOPURINE, METHOTREXATE, METHYLPREDNISOLONE, PEGASPARGASE, THIOGUANINE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05748171 | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | Phase 2 | 100 | ACUTE LYMPHOBLASTIC LEUKEMIA | INOTUZUMAB OZOGAMICIN | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| HC3 Chemotherapy vs Blinatumomab: deaths from any cause | 28 of 57 | 11 of 54 | 111 | NCT02393859 | Trial comparisons |
| HC3 Chemotherapy vs Blinatumomab: serious adverse events | 24 of 52 | 15 of 54 | 106 | NCT02393859 | Trial comparisons |
Papers from its trials30
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 39218935 | RESULT | 1 | PubMed |
| 42748428 | DERIVED | 1 | PubMed |
| 42154791 | DERIVED | 1 | PubMed |
| 41671463 | DERIVED | 4 | PubMed |
| 41592282 | DERIVED | 1 | PubMed |
| 40857670 | DERIVED | 1 | PubMed |
| 39984805 | DERIVED | 1 | PubMed |
| 39214018 | DERIVED | 1 | PubMed |
| 38848537 | DERIVED | 1 | PubMed |
| 38841802 | DERIVED | 1 | PubMed |
1 to 10 of 30
See all 30 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020511
GET https://conductscience.org/api/diseases/v1/MONDO_0020511/drugs?page=2